High Expression of GALNT7 Promotes Invasion and Proliferation of Glioma Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Nov 9

PMID 30405766

Citations 8

Authors

Shi Hua

Hongyan Li

Yuguang Liu

Jian Zhang

Yanhao Cheng

Chao Dai

Affiliations

Soon will be listed here.

Abstract

Polypeptide-N-acetyl-galactosaminlytransferase 7 (GALNT7), a member of the GalNAc-transferase family, has not been previously evaluated as a prognostic factor of glioblastoma (GBM) or low-grade glioma (LGG). Based on The Cancer Genome Atlas database and bioinformatics analyses, the expression of GALNT7 was demosntrated to be higher in GBM and LGG tissues than in normal brain tissue. The expression levels of GANLT7 were associated with age, tumor grade, survival rate, disease-free survival time and overall survival time. Gene correlation and gene-set enrichment analyses suggested that GALNT7 may affect the proliferative and invasive abilities of glioma cells through multiple signaling pathways, including regulation of the actin cytoskeleton, natural killer cell-mediated cytotoxicity, the janus kinase-signal transducer and activator of transcription (STAT) signaling pathway, cell adhesion molecules and extracellular matrix receptor interaction pathways. Furthermore, 5 target genes of GALNT7 involved in these signaling pathways were identified, including Crk, Rac family small GTPase 1, STAT3, poliovirus receptor and Tenascin C. In summary, high expression of GALNT7 was associated with poor prognosis of glioma, and may be used as an effective biomarker of glioma.

Citing Articles

Comprehensive pan-cancer analysis reveals the versatile role of GALNT7 in epigenetic alterations and immune modulation in cancer.

Liu Y, Sun Y, Xiao M, Li S, Shi S Heliyon. 2024; 10(11):e31515.

PMID: 38845941 PMC: 11153094. DOI: 10.1016/j.heliyon.2024.e31515.

MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness.

Puppo M, Valluru M, Croset M, Ceresa D, Iuliani M, Khan A Br J Cancer. 2023; 129(5):754-771.

PMID: 37443350 PMC: 10449914. DOI: 10.1038/s41416-023-02340-9.

TGIF1 overexpression promotes glioma progression and worsens patient prognosis.

Wang B, Ma Q, Wang X, Guo K, Liu Z, Li G Cancer Med. 2022; 11(24):5113-5128.

PMID: 35569122 PMC: 9761070. DOI: 10.1002/cam4.4822.

Prenatal Cadmium Exposure Alters Proliferation in Mouse CD4 T Cells LncRNA Snhg7.

McCall J, Varney M, Rice E, Dziadowicz S, Hall C, Blethen K Front Immunol. 2022; 12:720635.

PMID: 35087510 PMC: 8786704. DOI: 10.3389/fimmu.2021.720635.

miR-30b-5p inhibits proliferation, invasion, and migration of papillary thyroid cancer by targeting GALNT7 via the EGFR/PI3K/AKT pathway.

Wang Y, Wang C, Fu Z, Zhang S, Chen J Cancer Cell Int. 2021; 21(1):618.

PMID: 34819077 PMC: 8611849. DOI: 10.1186/s12935-021-02323-x.

References

Duan H, Li X, Hu H, Li Y, Cai Z, Mei X . Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma. Tumour Biol. 2015; 36(9):6679-89. PMC: 4644213. DOI: 10.1007/s13277-015-3356-8. View

Shan S, Fang L, Shatseva T, Rutnam Z, Yang X, Du W . Mature miR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways. J Cell Sci. 2013; 126(Pt 6):1517-30. DOI: 10.1242/jcs.122895. View

Maris D, Nica D, Mohan D, Moisa H, Ciurea A . Multidisciplinary management of adult low grade gliomas. Chirurgia (Bucur). 2014; 109(5):590-9. View

Lin Q, Mao K, Tian F, Yang J, Chen P, Xu J . Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes. Cancer Chemother Pharmacol. 2015; 77(2):269-80. DOI: 10.1007/s00280-015-2926-1. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Chen X, Ma W, Xu S, Liang Y, Fu Y, Pang B . The overexpression of epithelial cell adhesion molecule (EpCAM) in glioma. J Neurooncol. 2014; 119(1):39-47. DOI: 10.1007/s11060-014-1459-5. View

Shimizu T, Kurozumi K, Ishida J, Ichikawa T, Date I . Adhesion molecules and the extracellular matrix as drug targets for glioma. Brain Tumor Pathol. 2016; 33(2):97-106. DOI: 10.1007/s10014-016-0261-9. View

Chandramohan V, Bryant J, Piao H, Keir S, Lipp E, Lefaivre M . Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Arch Pathol Lab Med. 2017; 141(12):1697-1704. PMC: 6051547. DOI: 10.5858/arpa.2016-0580-OA. View

Mayer A, Schneider F, Vaupel P, Sommer C, Schmidberger H . Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. Int J Oncol. 2012; 41(4):1260-70. PMC: 3583842. DOI: 10.3892/ijo.2012.1555. View

10.

Machado C, Freitas A, Couto F . Enrichment analysis applied to disease prognosis. J Biomed Semantics. 2013; 4(1):21. PMC: 4126066. DOI: 10.1186/2041-1480-4-21. View

11.

Billadeau D, Brumbaugh K, Dick C, Schoon R, Bustelo X, Leibson P . The Vav-Rac1 pathway in cytotoxic lymphocytes regulates the generation of cell-mediated killing. J Exp Med. 1998; 188(3):549-59. PMC: 2212464. DOI: 10.1084/jem.188.3.549. View

12.

Zheng Q, Han L, Dong Y, Tian J, Huang W, Liu Z . JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Neuro Oncol. 2014; 16(9):1229-43. PMC: 4136898. DOI: 10.1093/neuonc/nou046. View

13.

Mueller C, deCarvalho A, Mikkelsen T, Lehman N, Calvert V, Espina V . Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. Cancer Res. 2013; 74(3):818-28. DOI: 10.1158/0008-5472.CAN-13-2172. View

14.

Gaziel-Sovran A, Segura M, Di Micco R, Collins M, Hanniford D, Vega-Saenz de Miera E . miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011; 20(1):104-18. PMC: 3681522. DOI: 10.1016/j.ccr.2011.05.027. View

15.

Kim I, Yang Y, Yoon S, Choi I, Kay C, Kwon H . Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas. Int J Oncol. 2001; 19(5):1041-7. DOI: 10.3892/ijo.19.5.1041. View

16.

Yukinaga H, Shionyu C, Hirata E, Ui-Tei K, Nagashima T, Kondo S . Fluctuation of Rac1 activity is associated with the phenotypic and transcriptional heterogeneity of glioma cells. J Cell Sci. 2014; 127(Pt 8):1805-15. DOI: 10.1242/jcs.139733. View

17.

Lu Q, Xu L, Li C, Yuan Y, Huang S, Chen H . miR-214 inhibits invasion and migration via downregulating GALNT7 in esophageal squamous cell cancer. Tumour Biol. 2016; 37(11):14605-14614. DOI: 10.1007/s13277-016-5320-7. View

18.

Li J, Liu X, Duan Y, Liu Y, Wang H, Lian S . Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas. Med Sci Monit. 2017; 23:3593-3602. PMC: 5540004. DOI: 10.12659/msm.903098. View

19.

Li W, Ma H, Sun J . MicroRNA‑34a/c function as tumor suppressors in Hep‑2 laryngeal carcinoma cells and may reduce GALNT7 expression. Mol Med Rep. 2014; 9(4):1293-8. DOI: 10.3892/mmr.2014.1929. View

20.

Brosicke N, Faissner A . Role of tenascins in the ECM of gliomas. Cell Adh Migr. 2015; 9(1-2):131-40. PMC: 4422794. DOI: 10.1080/19336918.2014.1000071. View